Oxford Biomedica plc Overview
Pro stress-test →Oxford Biomedica is a global quality and innovation-led cell and gene therapy CDMO specialising in viral vector therapies with 25+ years of expertise. The company operates through two segments: a high-growth CDMO platform serving major pharmaceutical clients and early-stage product development. OXB now expects revenues of £220–240 million in 2026, with growth rising 25–30% annually through 2028.
Strategic Profile
Pro stress-test →Oxford Biomedica is doubling down on its standalone strategy in viral vector contract manufacturing, pointing to strong demand, a robust pipeline and scalable capabilities. Under a new agreement with Bristol Myers Squibb, OXB is expected to commence commercial manufacturing in 2026 at facilities in Oxford, UK, and Durham, NC, US.
Competitive Landscape
Pro stress-test →Oxford Biomedica is a UK-headquartered CDMO specialising in cell and gene therapy with focus on viral vector technologies including lentiviral, AAV and adenoviral systems. The company competes with specialized CDMOs in the rapidly growing cell and gene therapy sector, differentiated by its proprietary LentiVector platform and established manufacturing capabilities.
Industry Context
Oxford Biomedica plc operates in Cell & Gene Therapy Contract Development and Manufacturing Organisation (CDMO).
Key facts
Founded: 1996 · Headquarters: Oxford, United Kingdom · Revenue: £166-169 million (FY 2025)